Enlicitide Chloride (MK-0616) is an investigational oral drug being developed mainly to treat high cholesterol (hypercholesterolemia) and prevent cardiovascular diseases like atherosclerosis by inhibiting PCSK9, which helps lower “bad” LDL cholesterol. It’s used in clinical trials to reduce LDL-C levels in patients with heart disease or high risk, showing promise as an effective oral alternative to injectable PCSK9 inhibitors. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Chloruro de enlicitida and MK-0616 (chloride). Its PubChem CID is 166642685.
Enlicitide chloride
| CAS No | 2407527-16-4 |
|---|---|
| Molecular Formula | C82H110ClFN14O15 |
| Molecular Weight | 1586.3 g/mol |
| Synonyms | [6-[[(11S,17S,20S,23S,27S,39S,42S,63S,66R)-47-fluoro-20-[(1R)-1-hydroxyethyl]-17-[(4-methoxyphenyl)methyl]-11,63-dimethyl-10,16,19,22,30,40,58,61,64,67,70-undecaoxo-28-oxa-1,9,15,18,21,24,31,41,51,62,65,68-dodecazanonacyclo[37.18.11.23,6.124,42.133,37.144,51.011,15.023,27.045,50]triheptaconta-3(73),4,6(72),33,35,37(71),44(69),45(50),46,48-decaen-66-yl]methylamino]-6-oxohexyl]-trimethylazanium chloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Enlicitide Chloride (MK-0616) is an investigational oral drug being developed mainly to treat high cholesterol (hypercholesterolemia) and prevent cardiovascular diseases like atherosclerosis by inhibiting PCSK9, which helps lower "bad" LDL cholesterol.
The listed CAS number is 2407527-16-4.
The listed molecular formula is C82H110ClFN14O15.
The listed molecular weight is 1586.3 g/mol.
The source lists Chloruro de enlicitida and MK-0616 (chloride).
It is listed as a commercial API with a peptide origin.